Liyi Jia

3.2k total citations
5 papers, 58 citations indexed

About

Liyi Jia is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Liyi Jia has authored 5 papers receiving a total of 58 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Liyi Jia's work include Breast Cancer Treatment Studies (3 papers), HER2/EGFR in Cancer Research (2 papers) and Advanced Breast Cancer Therapies (2 papers). Liyi Jia is often cited by papers focused on Breast Cancer Treatment Studies (3 papers), HER2/EGFR in Cancer Research (2 papers) and Advanced Breast Cancer Therapies (2 papers). Liyi Jia collaborates with scholars based in United States, Spain and Portugal. Liyi Jia's co-authors include Heather L. McArthur, Carsten Denkert, Javier Cortés, Sherko Kümmel, Seock‐Ah Im, Konstantinos Tryfonidis, Rebecca Dent, Masato Takahashi, Peter Schmid and Lajos Pusztai and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and JAMA Network Open.

In The Last Decade

Liyi Jia

4 papers receiving 57 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liyi Jia United States	4	47	18	14	12	7	5	58
Daphné t’Kint de Roodenbeke Belgium	4	43 0.9×	15 0.8×	20 1.4×	14 1.2×	18 2.6×	7	60
Arrien A. Bertram United States	2	57 1.2×	21 1.2×	32 2.3×	20 1.7×	8 1.1×	3	78
Blanca Ledezma United States	5	49 1.0×	7 0.4×	17 1.2×	12 1.0×	7 1.0×	11	52
Laura Murillo Spain	5	48 1.0×	20 1.1×	20 1.4×	4 0.3×	11 1.6×	14	63
Adrián Nervo Argentina	5	59 1.3×	35 1.9×	13 0.9×	5 0.4×	8 1.1×	12	71
Jade M. van Berge Henegouwen Netherlands	4	27 0.6×	10 0.6×	18 1.3×	5 0.4×	6 0.9×	12	40
Amy Stoll-D’Astice United States	4	69 1.5×	31 1.7×	17 1.2×	12 1.0×	16 2.3×	8	86
Gustavo Dix Junqueira Pinto Brazil	4	50 1.1×	28 1.6×	45 3.2×	8 0.7×	12 1.7×	5	84
Alain Gratet France	3	23 0.5×	9 0.5×	16 1.1×	5 0.4×	11 1.6×	7	43
Yiu-Keung Lau United States	4	29 0.6×	9 0.5×	20 1.4×	4 0.3×	6 0.9×	10	53

Countries citing papers authored by Liyi Jia

Since Specialization

Citations

This map shows the geographic impact of Liyi Jia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liyi Jia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liyi Jia more than expected).

Fields of papers citing papers by Liyi Jia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liyi Jia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liyi Jia. The network helps show where Liyi Jia may publish in the future.

Co-authorship network of co-authors of Liyi Jia

This figure shows the co-authorship network connecting the top 25 collaborators of Liyi Jia. A scholar is included among the top collaborators of Liyi Jia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liyi Jia. Liyi Jia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Dent, Rebecca, Javier Cortés, Lajos Pusztai, et al.. (2024). Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. JNCI Journal of the National Cancer Institute. 116(10). 1654–1663. 11 indexed citations

2.

Takahashi, Masato, Javier Cortés, Rebecca Dent, et al.. (2023). Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer. JAMA Network Open. 6(11). e2342107–e2342107. 23 indexed citations

3.

Rugo, Hope S., Joohyuk Sohn, Lucía González‐Cortijo, et al.. (2022). KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS1118–TPS1118. 7 indexed citations

4.

Cardoso, Fátima, Aditya Bardia, Fabrice André, et al.. (2019). KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS601–TPS601. 17 indexed citations

5.

Chen, Xing, et al.. (2016). Estimating the Pólya process. Communication in Statistics- Theory and Methods. 46(19). 9397–9406.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact